You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Details for Patent: 7,598,279

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,598,279 protect, and when does it expire?

Patent 7,598,279 protects XCOPRI and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.

Summary for Patent: 7,598,279

Title:	Neurotherapeutic azole compounds
Abstract:	Azole compounds containing carbamoyl group and pharmaceutically useful salts thereof are described. The compounds are effective anticonvulsants which are used in the treatment of disorders of the central nervous system, especially as anxiety, depression, convulsion, epilepsy, migraine, bipolar disorder, drug abuse, smoking, ADHD, obesity, sleep disorder, neuropathic pain, stroke, cognitive impairment, neurodegeneration, stroke and muscle spasm.
Inventor(s):	Choi; Yong Moon (Pinebrook, NJ), Kim; Choon-Gil (Daejon, KR), Yi; Han-Ju (Daejeon, KR), Kang; Young-Sun (Daejeon, KR), Lee; Hyun-Seok (Daejeon, KR)
Assignee:	SK Holdings Co., Ltd. (Seoul, KR)
Application Number:	11/407,526
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,598,279

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sk Life	XCOPRI	cenobamate	TABLET;ORAL	212839-001	Mar 10, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial		Y			⤷ Try a Trial
Sk Life	XCOPRI	cenobamate	TABLET;ORAL	212839-002	Mar 10, 2020		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial		Y			⤷ Try a Trial
Sk Life	XCOPRI	cenobamate	TABLET;ORAL	212839-003	Mar 10, 2020		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial		Y			⤷ Try a Trial
Sk Life	XCOPRI	cenobamate	TABLET;ORAL	212839-004	Mar 10, 2020		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial		Y			⤷ Try a Trial
Sk Life	XCOPRI	cenobamate	TABLET;ORAL	212839-005	Mar 10, 2020		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial		Y			⤷ Try a Trial
Sk Life	XCOPRI	cenobamate	TABLET;ORAL	212839-006	Mar 10, 2020		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial		Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,598,279

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	053065	⤷ Try a Trial
Australia	2006237798	⤷ Try a Trial
Brazil	PI0607529	⤷ Try a Trial
Canada	2606258	⤷ Try a Trial
China	101228138	⤷ Try a Trial
Denmark	1879873	⤷ Try a Trial
European Patent Office	1879873	⤷ Try a Trial	301106	Netherlands	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.